Key result
Pediatric COVID-19 is linked to lower ASCL1 expression versus non-COVID bronchial pneumonia.
Why the study?
The study was conducted to investigate the expression of neuropeptide family members and their correlation with inflammatory indicators in peripheral blood of children with COVID-19.
Observational (n=57)
p-value: p=0.04
ASCL1 is downregulated in pediatric COVID-19 and correlates negatively with inflammatory markers, suggesting a potential regulatory role in COVID-19-related inflammation.
Observational pediatric COVID-19 data should not change practice; leaves open neuropeptide-inflammatory biomarker roles for prospective validation.
OBJECTIVE: The purpose of this article is to investigate the expression of neuropeptide family members and their correlation with inflammatory indicators in the peripheral blood of children infected with COVID-19. METHODS: Blood samples were collected from 40 hospitalized newly diagnosed children with confirmed COVID-19 infection and 17 hospitalized children with non-COVID-19 bronchial pneumonia during the same period. Baseline clinical data were collected and analyzed. Expression and correlation analysis of neuropeptide-related molecules [ACE (Angiotensin Converting Enzyme), ACE2 (Angiotensin Converting Enzyme 2), ASCL1 (achaete-scute family bHLH transcription factor 1)] in peripheral blood were detected and analyzed by ELISA. Complete blood counts with differentials, C-Reactive Protein (CRP), liver enzymes, Substance P (SP), Vasoactive Intestinal Polypeptide (VIP), and Gastrin-Releasing Peptide (GRP) were also measured. RESULTS: The results of 40 COVID-19 patients (43% males) and 17 non-COVID-19 patients (71% males) were compared. ACE2 in non-COVID-19 and moderate COVID-19 groups was higher than that in severe groups (p=0.04; p=0.03, respectively). ASCL1 in the non-COVID-19 group was higher than that in the COVID-19 group (p=0.04). ASCL1 in the non-COVID group was higher than that in the severe COVID group (p=0.02). There were no significant differences in SP, VIP, and GRP between COVID-19 and non-COVID-19 groups. ASCL1 correlated negatively with blood neutrophils (%) (r = -0.534, p<0.001), CRP (r = -0.522, p<0.001), but positively with lymphocytes (%) (r = 0.572, p<0.001), and aspartate aminotransferase (r = 0.496, p=0.001). There was no significant correlation between SCL1 and white blood cell count, platelet count, alanine transaminase, or Lactate dehydrogenase. DISCUSSION: The negative correlation between ASCL1 and neutrophil percentage (N%) and CRP suggests that ASCL1 may modulate the inflammation associated with pediatric COVID-19, positioning it as a potential biomarker and therapeutic target. The study's findings suggest that ASCL1 is downregulated in pediatric COVID-19 and correlates negatively with neutrophil percentage and CRP, indicating a potential regulatory role in COVID-19-related inflammation. Unlike adults, ACE/ACE2 are not highly expressed in children, which may partly explain the milder disease course. ASCL1 may represent a novel biomarker and therapeutic target worthy of further investigation in larger pediatric cohorts. CONCLUSION: Unlike adults, ACE and ACE2 are not highly expressed in children with COVID-19. ASCL1 in children with COVID-19 is lower than that in non-COVID-19 children. ASCL1 is negatively correlated with N% and CRP, suggesting that ASCL1 may have a role in COVID-19 inflammation.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) conducted an observational in COVID-19 (n=57). COVID-19 infection vs. Non-COVID-19 bronchial pneumonia was evaluated on Expression of neuropeptide-related molecules (ACE, ACE2, ASCL1) in peripheral blood (p=0.04). ASCL1 expression was significantly lower in children with COVID-19 compared to those with non-COVID-19 bronchial pneumonia (p=0.04) and correlated negatively with neutrophil percentage and CRP.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: